Compare Boston Beer Company Inc (SAM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Beer Company Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Boston Beer Company Inc trades at $171.63 (market cap $1.73B), while State Street SPDR S&P Biotech ETF trades at $149.94 (market cap $10.08B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 5.8× Boston Beer Company Inc's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Boston Beer Company Inc for 59 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| SAM | XBI | |
|---|---|---|
Market Cap | $1.73B | $10.08B |
Volume | 196,621 | 9,534,635 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $260.05 | $169.55 |
52-Week Low | $161.08 | $104.99 |
Typical Hold Time | 59 Days | 37 Days |
Enterprise Value | $1.50B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Beer Company (SAM) trades at $168.16, down 1.3% with a neutral technical outlook. The stock shows mixed fundamentals with a P/E of 22.66 and P/S of 0.92, but negative net income margin of -3.64% and ROE of -8.61%. Recent earnings missed expectations in Q1 and Q2 2026, though Q4 2025 beat estimates. The company maintains positive operating cash flow of $270M in 2025 while expanding brand innovation with new product launches and marketing initiatives.
SAM faces headwinds from volume declines and cost pressures, but brand investments and new product categories offer growth potential. Analyst consensus is cautious with 72% hold ratings, though the $204.44 price target suggests 22% upside. Key risks include competitive pressures and shifting consumer preferences in the alcoholic beverage market.
XBI trades at $150.23, down 0.44% on the day, with bearish technical signals dominating. The ETF faces resistance near $152-154 while finding support at $147-149 levels. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech sector optimism from M&A activity and cancer vaccine breakthroughs. The fund's 0.35% expense ratio compares unfavorably to broader healthcare ETFs but offers targeted biotech exposure.
Outlook remains mixed with technical weakness offset by sector catalysts. The biotech focus provides growth potential but carries higher volatility than diversified healthcare alternatives. Key risks include sector-specific regulatory pressures and the fund's expense structure, while opportunities exist from ongoing pharmaceutical innovation and capital market improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
